ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access
October 15, 2018Sandoz, a Novartis division and the global leader in biosimilars, announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz® (adalimumab)[1] for reference medicine Humi
Pharma Sources Insight January 2025
